In this issue:
- Tisa-cel vs. axi-cel in relapsed/refractory DLBCL
- Liso-cel vs. standard of care, as second-line, in relapsed/refractory LBCL
- PROs for axi-cel, as second-line, in LBCL
- Anti-CD19 CAR T-cells for B-cell ALL with CNS involvement
- Next-day manufacture of anti-CD19 CAR T-cells for B-cell ALL
- Long-term follow-up of anti-BCMA + CD19 CAR T-cells in myeloma
- Disparities in immune checkpoint inhibitor trials
- Mosunetuzumab for relapsed/refractory follicular lymphoma
- Teclistamab in relapsed/refractory myeloma
- OS with brentuximab vedotin in stage III–IV Hodgkin lymphoma
Download PDF